Skip to content
Menu

Avalo Therapeutics, Inc. AVTX

Full chart Compare
Set alert

Price alert · AVTX

All alert types
6.75 USD +0.05 (+0.75%)

Regular-session close

6.75 0.00 0.00%

After hours · Nov 19, 4:01 PM ET

6.53 Day range 6.87
6.53 52-week range 24.27
YTD
-62.83%
1 year
-61.63%

 

No chart data for this range yet.
Market cap
390.31M
Revenue (ttm)
59.00K
EPS (ttm)
-2.26
Shares out
53.63M
Forward P/E
-7.19
YTD return
-62.83%
1-year return
-61.63%
50-day average
19.11
200-day average
16.92
Volume
710.44K
Avg volume
1.79M
Open
6.73
Previous close
6.70
Day's range
6.53 – 6.87
52-week range
6.53 – 24.27
Beta
0.79
Analysts
Strong Buy
Price target
44.08 (+553.1%)

Key statistics

Enterprise value
631.27M
Price / sales
17916.05
Price / book
2.32
Free cash flow
-23.27M
Total cash
400.28M
Total debt
242.00K
Return on equity
-36.27%
Short % of float
24.45%

Fundamental scorecard

7 of 25 checks passed on AVTX’s reported financials

ValueGrowthProfitabilityHealthDividend

7of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
AVTX Revenue — quarterly 0
AVTX Net income — quarterly -18.95M
AVTX EPS — quarterly -0.34

Earnings

AVTX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 5, 2026Sep 30, 2026-0.56337———
Aug 6, 2026Jun 30, 2026-0.58273-0.83-0.25-42.43%
May 13, 2026Mar 31, 2026-1.00-0.98+0.02+2.00%
Mar 23, 2026Dec 31, 2025-1.54-0.74+0.80+51.95%
Nov 6, 2025Sep 30, 2025-1.67-2.19-0.52-31.14%
Aug 7, 2025Jun 30, 2025-1.43-1.92-0.49-34.27%

Upgrades / downgrades

AVTX analyst upgrades and downgrades
DateFirmActionFromTo
Aug 7, 2026GuggenheimmainBuyBuy
Aug 7, 2026HC Wainwright & Co.mainBuyBuy
Jul 6, 2026Leerink Partnersinit—Outperform
Jun 16, 2026BTIGreitBuyBuy
Jun 12, 2026B of A Securitiesinit—Buy
May 14, 2026CitizensmainMarket OutperformMarket Outperform

About Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
avalotx.com

News

Your note

Sign in to keep a note on AVTX — it syncs with the Stock Master app.

Insider holders

AVTX insider holders
InsiderRelationLatest transactionDateShares held
ALMENOFF JUNE SHERIEDirectorConversion of Exercise of derivative securityMar 27, 20254,167
DOYLE MITTIEOfficerSaleAug 27, 202651,776
GOLDMAN JONATHANDirectorConversion of Exercise of derivative securityMar 26, 20263,166
KANTOFF AARONDirectorConversion of Exercise of derivative securityMar 26, 20266,333
KAPLAN GILLADirectorConversion of Exercise of derivative securityMar 26, 20266,333
NEIL GARRY A. M.D.Chief Executive OfficerStock Award(Grant)May 20, 2026190,314

Institution ownership

AVTX institution ownership
Holder% heldSharesValueReported
FMR, LLC9.51%5,100,216100.53MJun 29, 2026
Blackrock Inc.8.14%4,365,55386.05MJun 29, 2026
Deep Track Capital, Lp6.73%3,610,00071.15MJun 29, 2026
Caligan Partners, LP5.90%3,163,86662.36MJun 29, 2026
TCG Crossover Management, LLC5.63%3,017,12059.47MJun 29, 2026
Affinity Asset Advisors, Llc5.41%2,900,00057.16MJun 29, 2026

Fund ownership

AVTX fund ownership
Holder% heldSharesValueReported
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF3.78%2,029,49240.00MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.12%1,675,49833.02MJun 29, 2026
Fidelity Capital Trust-Fidelity Stock Selector Small Cap Fund2.25%1,208,90023.83MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.04%1,093,32621.55MJun 29, 2026
Fidelity Securities Fund-Fidelity Series Small Cap Opportunities Fund1.33%715,70014.11MJun 29, 2026
Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund1.19%639,70012.61MJul 30, 2026